Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Arthritis, Rheumatoid 8Melanoma 7Colitis, Ulcerative 6Inflammatory Bowel Diseases 5Crohn Disease 5Colitis 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Spondylitis, Ankylosing 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Psoriasis 1Precancerous Conditions 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 23aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Biopsy 7dabrafenib 6Surveys and Questionnaires 6Dacarbazine 6trametinib 5binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Blood Specimen Collection 5Aminolevulinic Acid 5sonidegib 4encorafenib 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Educational Status 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Infliximab × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡